Systematic review finds that α-blockers and 5α-reductase inhibitors improve urinary symptoms in BPH, suggesting better outcomes compared to single treatments.
Combination therapy with α-ABs and 5α-RIs demonstrates superior efficacy compared with monotherapy in improving urinary symptoms, reducing prostate volume, increasing urinary flow rate, lowering PSA levels, and decreasing the risks of AUR and postoperative surgery, with a favorable safety profile. For BPH patients with severe symptoms and larger prostate volumes, combination therapy is recommended to achieve optimal therapeutic outcomes.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: